15

Genscript Biotech CorpHKG 1548 Stock Report

Last reporting period 31 Dec, 2023

Updated 19 Sep, 2024

Last price

Market cap $B

3.217

Middle

Exchange

XHKG - Hong Kong Exchange

1548.HK Stock Analysis

15

Uncovered

Genscript Biotech Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-12/100

Low score

Market cap $B

3.217

Dividend yield

0.35 %

Shares outstanding

2 103.26 B

Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. The company is headquartered in Nanjing, Jiangsu and currently employs 5,573 full-time employees. The company went IPO on 2015-12-30. The firm operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.

View Section: Eyestock Rating